And Anticonvulsant Effects of Anesthetics (Part I)

Total Page:16

File Type:pdf, Size:1020Kb

And Anticonvulsant Effects of Anesthetics (Part I) ANESTH ANALG 303 1990:70:30>15 Review Article Pro- and Anticonvulsant Effects of Anesthetics (Part I) Paul A. Modica, MD, Rene Tempelhoff, MD, and Paul F. White, rhD, MD Key Words: ANTICONVULSANTS. BRAIN, PRO- An epileptic seizure has been defined as a sudden AND ANTICONWLSANTS. COMPLICATIONS, alteration of central nervous system (CNS) function CONVULSIONS. TOXICITY, CONVULSIONS. resulting from a high-voltage electrical discharge. This discharge may arise from an assemblage of Part I neurons in either cortical or subcortical tissues. The Introduction spread of this excitatory activity to the subcortical, Inhalation anesthetics Volatile agents thalamic, and brainstem centers corresponds to the Enflurane tonic phase of the seizure and loss of consciousness Halothane (1). In contrast, myoclonic activity refers to a series of Isoflurane rhythmic or arrhythmic muscular contractions (2). Investigational volatile agents Depending on the electroencephalographic (EEG) Nitrous oxide findings, myoclonus is divided into epileptic and Intravenous analgesics nonepileptic activity (3). Nonepileptic myoclonus Opioid (narcotic) analgesics originates from the brainstem or spinal cord and is Meperidine due to either loss of cortical inhibition (4)or to im- Morphine paired function of spinal interneurons (3,5). Without Fentanyl and its analogues EEG monitoring, it is extremely difficult to determine Summary whether abnormal-appearing seizurelike muscle Part I1 movements are due to epileptiform activity or non- Introduction epileptic myoclonia. Intravenous anesthetics Many anesthetic and analgesic drugs have been Sedative-hypnotics reported to cause seizure activity clinically (Table 1, Barbiturates A). Interestingly, many of these same drugs have also Etomidate been shown to possess anticonvulsant properties Benzodiazepines (Table 1, B). In an effort to explain deficiencies with Ketamine Guedel's original stages of anesthesia, Winters and Propofol colleagues (67) proposed a multidirectional contin- Local anesthetics uum of anesthetic states (Figure 1). For example, Anesthetic adjuncts some agents (e.g., diethyl ether) traverse both CNS Muscle relaxants excitation (stages I, 11) and depression (stage 111). Anticholinesterases Others (e.g., halothane, ultrashort acting barbitu- Anticholinergics rates) progress directly from stage I to 111, whereas Summary still others (e.g., nitrous oxide [N,O], enflurane, ketamine, and narcotics [S]) induce a stage I1 catalep- Part 11 of this review article will appear in the following issue of toid CNS excitation, which on occasion progresses to the journal. Received from the Department of Anesthesiology, Washington myoclonia or generalized convulsions. Based on EEG University school of Medicine, St. Louis, Missouri. Accepted for studies in cats, Winters suggested that both exces- publication October 10,1989. sively disorganized (stage 11) and decreased reticular- Address correspondenceto Dr. White, Department of Anesthe- siology, Box 8054, Washington University School of Medicine, 660 formation activity (stage 111) result in unresponsive- South Euclid Avenue, St. Louis, MO 63110. ness to painful stimuli and amnesia, consistent with 01990 by the International Anesthesia Research Society ANESTH ANALG MODICA ET AL. 304 1990;7030>15 Table 1. Anesthetics and Analgesics Reported to Cause stage 111 agent, has been used in the diagnostic and/or Suppress Seizure Activity in Humans activation of epileptogenic foci (11,12). ~ A. Proconvulsants 8.Anticonvulsants To properly categorize the various anesthetic Nitrous oxide Halothane agents with respect to their effects on the seizure Halothane Enflurance threshold, there are several important factors to con- Enflurane Isoflurane sider. The first consideration is the patient population Isoflurane Thiopental studied. For example, methohexital, in its current Morphine E tomida te formulation (Brevital; Eli Lilly, Indianapolis, Ind.), Meperidine Diazepam Fentanyl Lorazepam will only produce epileptiform activity in patients Sufentanil Midazolam with known seizure disorders (11,12). A second fac- Methohexital Ketamine tor to consider is the method of proconvulsant and Etomidate Prop of o1 anticonvulsant documentation. This had led to con- Diazepam Local anesthetics fusion in the literature regarding the effects of some Ketamine Propofol anesthetics and analgesics on CNS activity. Fentanyl- Local anesthetics induced seizures have been described clinically with- out the support of EEG documentation (13-15). In some instances, these convulsivelike muscle move- ME TRAZOL, KETAMINE ments may be due to nonepileptic myoclonus. PHENCYCLIOINE f-7 Y HYDROXYBUTYRATE SE, ZUR ES For most drugs used in anesthesia, subsequent EEG evaluation during their administration has MESCAL IN& N20 helped to clarify whether or not a particular agent is ETHER( truly epileptogenic in patients. However, for certain anesthetics, such as ketamine (16), the origin of epileptiform activity involves subcortical neuronal pathways. In humans, subcortical seizures are de- tected only with implanted EEG depth electrodes, not by standard surface leads. Thus, a third important factor to consider in determining whether or not an anesthetic possesses proconvulsant or anticonvulsant properties is the type of EEG recording electrodes (surface or depth) used during its evaluation. In this review article, we have attempted to ana- lyze the evidence for proconvulsant and anticonvul- sant activity of anesthetics and analgesics. This infor- mation has been evaluated with respect to (a) patient population (epileptic or nonepileptic); (b) documen- Figure 1. Winter's proposed scheme of reversible progression of tation of pro- and anticonvulsant activity (EEG study CNS states induced by various anesthetic and excitant agents. Stages I, 11, A, B, C, myoclonus, and seizures indicate CNS or clinical report); and (c) method of EEG analysis excitation, whereas stages Ill and IV indicate CNS depression. (surface or depth electrodes). (From Winters WD, Ferrer-Allado T, Guzman-Flores C, Alcaraz M. The cataleptic state induced by ketamine: a review of the neuro- pharmacology of anesthesia. Neuropharmacology 1972;11:30>15, with permission.) Inhala tion Anesthetics Volatile Agents the anesthetic state. Although both epileptic and anesthetic states possess similar features regarding Enflurune. Abnormal movements consisting of arousal and memory, the categorization proposed by twitching of individual muscle groups, and even Winters fails to adequately explain the actions of tonic-clonic activity, were frequently observed during those anesthetics that appear to possess both procon- the early clinical evaluation of enflurane (17,18). vulsant and anticonvulsant properties (Table 1). For Subsequent EEG recordings in normal patients dem- example, ketamine, an alleged stage I1 anesthetic onstrated epileptiform activity (19,20) and grand ma1 which Winters believed to be contraindicated in epi- seizure patterns (21) (Table 2). These findings with lepsy, has been successfully used to terminate status enflurane have also been confirmed in patients with epilepticus (9, lo), and conversely, methohexital, a temporal lobe epilepsy during both electrocortico- ANESTHETICS AND SEIZURES ANESTH ANALC 305 1990:70:30>15 Table 2. Proconvulsant Effects of Inhalation Anesthetics in Humans Seizure documentation Type of EEG Clinical EEG electrodes Agent Population report study used in study References Nitrous oxide Nonepileptic + - Surface 58, 64, 96 Epileptic - - Depth 16 Halothane Nonepileptic - - Surface 6M2 Epileptic - - Surface 63 Enflurance Nonepileptic + i Surface 17-21, 26, 28 Epileptic + i Surfaceldepth 22-25 lsoflurane Nonepileptic - - Surface 75-78 Epileptic NIA N/A Sevoflurane Nonepileptic - - Surface 86 Epileptic NIA NIA Desflurane (1-653) Nonepileptic NIA N/A Epileptic N/A NIA +, presence of seizures; -, absence of seizures; EEC, electroencephalographic; N/A, information not available. owdm LO m Figure 2. Electroencephalographic patterns with increasing concentrations of enflurane. (From Neigh JL, Garman JK, Harp JR. The 0 electroencephalographic pattern during anes- thesia with Ethrane: effects of depth of anes- thesia, Paco,, and nitrous oxide. Anesthesiol- &6 ogy 1971;35:482-7, with permission.) 15 graphic (22-24) and depth electrode recordings (25). waves-spike and dome activity with intermittent In ten healthy volunteers, grand ma1 seizure patterns periods of burst suppression (Figure 2). In contrast to were precipitated by auditory, visual, and tactile other volatile anesthetics, these burst suppression stimulation at end-tidal enflurane concentrations of patterns are thought to represent an excitatory event 3%-6% (26). This has also been reported during otic (29). microsurgery (27). In both normal (28) and epileptic The ability of enflurane to produce seizure or EEG (U)patients, increasing depth of enflurane anesthe- spiking activity is influenced by both its concentra- sia is characterized by the appearance of high-voltage tion and the Paco, (25,28). At a normal Paco, level, spikes, with the subsequent development of spike spiking is maximal at inspired enflurane concentra- 306 ANESTH ANALG MODICA ET AL. 1990;70303-15 tions of 2%-3%. Higher Paco, concentrations reduce thiopental (42) were found to intensify enflurane- spiking activity (22). Interestingly, N,O does not induced seizures in humans. Larger doses of thiopen- affect the tendency of enflurane to produce spiking tal diminished seizure activity. In cats, enhanced activity (28). With
Recommended publications
  • Amnestic Concentrations of Sevoflurane Inhibit Synaptic
    Anesthesiology 2008; 108:447–56 Copyright © 2008, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Amnestic Concentrations of Sevoflurane Inhibit Synaptic Plasticity of Hippocampal CA1 Neurons through ␥-Aminobutyric Acid–mediated Mechanisms Junko Ishizeki, M.D.,* Koichi Nishikawa, M.D., Ph.D.,† Kazuhiro Kubo, M.D.,‡ Shigeru Saito, M.D., Ph.D.,§ Fumio Goto, M.D., Ph.D.࿣ Background: The cellular mechanisms of anesthetic-induced for surgical procedures do not have recollection of ac- amnesia are still poorly understood. The current study exam- tually being awake despite being awake and cooperative ined sevoflurane at various concentrations in the CA1 region of during the procedure.1 Galinkin et al.2 compared sub- rat hippocampal slices for effects on excitatory synaptic trans- Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/108/3/447/366512/0000542-200803000-00017.pdf by guest on 29 September 2021 mission and on long-term potentiation (LTP), as a possible jective, psychomotor, cognitive, and analgesic effects of mechanism contributing to anesthetic-induced loss of recall. sevoflurane (0.3% and 0.6%) with those of nitrous oxide Methods: Population spikes and field excitatory postsynaptic at equal minimum alveolar concentrations (MACs) in potentials were recorded using extracellular electrodes after healthy volunteers. They found that sevoflurane pro- electrical stimulation of Schaffer-collateral-commissural fiber inputs. Paired pulse facilitation was used as a measure of pre- duced a greater degree of amnesia and psychomotor synaptic effects of the anesthetic. LTP was induced using tetanic impairment than did an equal MAC of nitrous oxide but stimulation (100 Hz, 1 s). Sevoflurane at concentrations from had no analgesic actions.
    [Show full text]
  • Picrotoxin-Like Channel Blockers of GABAA Receptors
    COMMENTARY Picrotoxin-like channel blockers of GABAA receptors Richard W. Olsen* Department of Molecular and Medical Pharmacology, Geffen School of Medicine, University of California, Los Angeles, CA 90095-1735 icrotoxin (PTX) is the prototypic vous system. Instead of an acetylcholine antagonist of GABAA receptors (ACh) target, the cage convulsants are (GABARs), the primary media- noncompetitive GABAR antagonists act- tors of inhibitory neurotransmis- ing at the PTX site: they inhibit GABAR Psion (rapid and tonic) in the nervous currents and synapses in mammalian neu- system. Picrotoxinin (Fig. 1A), the active rons and inhibit [3H]dihydropicrotoxinin ingredient in this plant convulsant, struc- binding to GABAR sites in brain mem- turally does not resemble GABA, a sim- branes (7, 9). A potent example, t-butyl ple, small amino acid, but it is a polycylic bicyclophosphorothionate, is a major re- compound with no nitrogen atom. The search tool used to assay GABARs by compound somehow prevents ion flow radio-ligand binding (10). through the chloride channel activated by This drug target appears to be the site GABA in the GABAR, a member of the of action of the experimental convulsant cys-loop, ligand-gated ion channel super- pentylenetetrazol (1, 4) and numerous family. Unlike the competitive GABAR polychlorinated hydrocarbon insecticides, antagonist bicuculline, PTX is clearly a including dieldrin, lindane, and fipronil, noncompetitive antagonist (NCA), acting compounds that have been applied in not at the GABA recognition site but per- huge amounts to the environment with haps within the ion channel. Thus PTX major agricultural economic impact (2). ͞ appears to be an excellent example of al- Some of the other potent toxicants insec- losteric modulation, which is extremely ticides were also radiolabeled and used to important in protein function in general characterize receptor action, allowing and especially for GABAR (1).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • Exploring the Activity of an Inhibitory Neurosteroid at GABAA Receptors
    1 Exploring the activity of an inhibitory neurosteroid at GABAA receptors Sandra Seljeset A thesis submitted to University College London for the Degree of Doctor of Philosophy November 2016 Department of Neuroscience, Physiology and Pharmacology University College London Gower Street WC1E 6BT 2 Declaration I, Sandra Seljeset, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I can confirm that this has been indicated in the thesis. 3 Abstract The GABAA receptor is the main mediator of inhibitory neurotransmission in the central nervous system. Its activity is regulated by various endogenous molecules that act either by directly modulating the receptor or by affecting the presynaptic release of GABA. Neurosteroids are an important class of endogenous modulators, and can either potentiate or inhibit GABAA receptor function. Whereas the binding site and physiological roles of the potentiating neurosteroids are well characterised, less is known about the role of inhibitory neurosteroids in modulating GABAA receptors. Using hippocampal cultures and recombinant GABAA receptors expressed in HEK cells, the binding and functional profile of the inhibitory neurosteroid pregnenolone sulphate (PS) were studied using whole-cell patch-clamp recordings. In HEK cells, PS inhibited steady-state GABA currents more than peak currents. Receptor subtype selectivity was minimal, except that the ρ1 receptor was largely insensitive. PS showed state-dependence but little voltage-sensitivity and did not compete with the open-channel blocker picrotoxinin for binding, suggesting that the channel pore is an unlikely binding site. By using ρ1-α1/β2/γ2L receptor chimeras and point mutations, the binding site for PS was probed.
    [Show full text]
  • Characterization of Strychnine Binding Sites in the Rodent
    CHARACTERIZATION OF STRYCHNINE BINDING SITES IN THE RODENT SPINAL CORD BY VINCENT MAURICE O’CONNOR UNIVERSITY COLLEGE LONDON A thesis submitted for the degree of Doctor of Philosophy from the University of London, 1992. I ProQuest Number: 10608898 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 10608898 Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 This thesis is dedicated to the select band o f people, including the most recent arrivals and the sorely missed departed, that I hold closest in my affections. "At the end of the day" they make It all worthwhile. Remember, in the words of the famous actor whose name at present escapes me; "Nobody said it would be easy". Although my own feeling is that Nobody was probably wrong. II Thesis abstract The convulsant alkaloid strychnine is a selective and highly potent antagonist at postsynaptic receptor for the inhibitory neurotransmitter glycine . These properties have led to the extensive use of strychnine as a ligand to probe the postsynaptic glycine receptor. Despite the recent increased understanding of the molecular structure of this receptor protein there is still much dispute as to the nature of the interaction between glycine and strychnine.
    [Show full text]
  • Chronic Social Isolation Reduces 5-HT Neuronal Activity Via Upregulated SK3 Calcium-Activated Potassium Channels Derya Sargin1, David K Oliver1, Evelyn K Lambe1,2,3*
    SHORT REPORT Chronic social isolation reduces 5-HT neuronal activity via upregulated SK3 calcium-activated potassium channels Derya Sargin1, David K Oliver1, Evelyn K Lambe1,2,3* 1Department of Physiology, University of Toronto, Toronto, Canada; 2Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Canada; 3Department of Psychiatry, University of Toronto, Toronto, Canada Abstract The activity of serotonin (5-HT) neurons is critical for mood regulation. In a mouse model of chronic social isolation, a known risk factor for depressive illness, we show that 5-HT neurons in the dorsal raphe nucleus are less responsive to stimulation. Probing the responsible cellular mechanisms pinpoints a disturbance in the expression and function of small-conductance Ca2+-activated K+ (SK) channels and reveals an important role for both SK2 and SK3 channels in normal regulation of 5-HT neuronal excitability. Chronic social isolation renders 5-HT neurons insensitive to SK2 blockade, however inhibition of the upregulated SK3 channels restores normal excitability. In vivo, we demonstrate that inhibiting SK channels normalizes chronic social isolation- induced anxiety/depressive-like behaviors. Our experiments reveal a causal link for the first time between SK channel dysregulation and 5-HT neuron activity in a lifelong stress paradigm, suggesting these channels as targets for the development of novel therapies for mood disorders. DOI: 10.7554/eLife.21416.001 Introduction *For correspondence: evelyn. Major depression is a prevalent and debilitating disease for which standard treatments remain inef- [email protected] fective. Social isolation has long been implicated as a risk factor for depression in humans Competing interests: The (Cacioppo et al., 2002,2006; Holt-Lunstad et al., 2010) and induces anxiety- and depressive-like authors declare that no behaviors in rodents (Koike et al., 2009; Wallace et al., 2009; Dang et al., 2015; Shimizu et al., competing interests exist.
    [Show full text]
  • Toxicological and Pharmacological Profile of Amanita Muscaria (L.) Lam
    Pharmacia 67(4): 317–323 DOI 10.3897/pharmacia.67.e56112 Review Article Toxicological and pharmacological profile of Amanita muscaria (L.) Lam. – a new rising opportunity for biomedicine Maria Voynova1, Aleksandar Shkondrov2, Magdalena Kondeva-Burdina1, Ilina Krasteva2 1 Laboratory of Drug metabolism and drug toxicity, Department “Pharmacology, Pharmacotherapy and Toxicology”, Faculty of Pharmacy, Medical University of Sofia, Bulgaria 2 Department of Pharmacognosy, Faculty of Pharmacy, Medical University of Sofia, Bulgaria Corresponding author: Magdalena Kondeva-Burdina ([email protected]) Received 2 July 2020 ♦ Accepted 19 August 2020 ♦ Published 26 November 2020 Citation: Voynova M, Shkondrov A, Kondeva-Burdina M, Krasteva I (2020) Toxicological and pharmacological profile of Amanita muscaria (L.) Lam. – a new rising opportunity for biomedicine. Pharmacia 67(4): 317–323. https://doi.org/10.3897/pharmacia.67. e56112 Abstract Amanita muscaria, commonly known as fly agaric, is a basidiomycete. Its main psychoactive constituents are ibotenic acid and mus- cimol, both involved in ‘pantherina-muscaria’ poisoning syndrome. The rising pharmacological and toxicological interest based on lots of contradictive opinions concerning the use of Amanita muscaria extracts’ neuroprotective role against some neurodegenerative diseases such as Parkinson’s and Alzheimer’s, its potent role in the treatment of cerebral ischaemia and other socially significant health conditions gave the basis for this review. Facts about Amanita muscaria’s morphology, chemical content, toxicological and pharmacological characteristics and usage from ancient times to present-day’s opportunities in modern medicine are presented. Keywords Amanita muscaria, muscimol, ibotenic acid Introduction rica, the genus had an ancestral origin in the Siberian-Be- ringian region in the Tertiary period (Geml et al.
    [Show full text]
  • General Anesthetic Actions on GABAA Receptors Paul Garcia, Emory University Scott E
    General Anesthetic Actions on GABAA Receptors Paul Garcia, Emory University Scott E. Kolesky, Emory University Andrew Jenkins, Emory University Journal Title: Current Neuropharmacology Volume: Volume 8, Number 1 Publisher: Bentham Science Publishers | 2010-03, Pages 2-9 Type of Work: Article | Final Publisher PDF Publisher DOI: 10.2174/157015910790909502 Permanent URL: http://pid.emory.edu/ark:/25593/fkg4m Final published version: http://www.eurekaselect.com/71259/article Copyright information: ©2010 Bentham Science Publishers Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution 2.5 Generic License ( http://creativecommons.org/licenses/by/2.5/), which permits distribution, public display, and publicly performance, distribution of derivative works, making multiple copies, provided the original work is properly cited. This license requires credit be given to copyright holder and/or author. Accessed September 28, 2021 5:01 PM EDT 2 Current Neuropharmacology, 2010, 8, 2-9 General Anesthetic Actions on GABAA Receptors Paul S. Garcia, Scott E. Kolesky and Andrew Jenkins* Departments of Anesthesiology and Pharmacology, Emory University, School of Medicine, Rollins Research Center #5013, 1510 Clifton Rd NE, Atlanta GA, USA Abstract: General anesthetic drugs interact with many receptors in the nervous system, but only a handful of these inter- actions are critical for producing anesthesia. Over the last 20 years, neuropharmacologists have revealed that one of the most important target sites for general
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Bicuculline and Gabazine Are Allosteric Inhibitors of Channel Opening of the GABAA Receptor
    The Journal of Neuroscience, January 15, 1997, 17(2):625–634 Bicuculline and Gabazine Are Allosteric Inhibitors of Channel Opening of the GABAA Receptor Shinya Ueno,1 John Bracamontes,1 Chuck Zorumski,2 David S. Weiss,3 and Joe Henry Steinbach1 Departments of 1Anesthesiology and 2Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110, and 3University of Alabama at Birmingham, Neurobiology Research Center and Department of Physiology and Biophysics, Birmingham, Alabama 35294-0021 Anesthetic drugs are known to interact with GABAA receptors, bicuculline only partially blocked responses to pentobarbital. both to potentiate the effects of low concentrations of GABA and These observations indicate that the blockers do not compete to directly gate open the ion channel in the absence of GABA; with alphaxalone or pentobarbital for a single class of sites on the however, the site(s) involved in direct gating by these drugs is not GABAA receptor. Finally, at receptors containing a1b2(Y157S)g2L known. We have studied the ability of alphaxalone (an anesthetic subunits, both bicuculline and gabazine showed weak agonist steroid) and pentobarbital (an anesthetic barbiturate) to directly activity and actually potentiated responses to alphaxalone. These activate recombinant GABAA receptors containing the a1, b2, and observations indicate that the blocking drugs can produce allo- g2L subunits. Steroid gating was not affected when either of two steric changes in GABAA receptors, at least those containing this mutated b2 subunits [b2(Y157S) and b2(Y205S)] are incorporated mutated b2 subunit. We conclude that the sites for binding ste- into the receptors, although these subunits greatly reduce the roids and barbiturates do not overlap with the GABA-binding site.
    [Show full text]
  • Increased NMDA Receptor Inhibition at an Increased Sevoflurane MAC Robert J Brosnan* and Roberto Thiesen
    Brosnan and Thiesen BMC Anesthesiology 2012, 12:9 http://www.biomedcentral.com/1471-2253/12/9 RESEARCH ARTICLE Open Access Increased NMDA receptor inhibition at an increased Sevoflurane MAC Robert J Brosnan* and Roberto Thiesen Abstract Background: Sevoflurane potently enhances glycine receptor currents and more modestly decreases NMDA receptor currents, each of which may contribute to immobility. This modest NMDA receptor antagonism by sevoflurane at a minimum alveolar concentration (MAC) could be reciprocally related to large potentiation of other inhibitory ion channels. If so, then reduced glycine receptor potency should increase NMDA receptor antagonism by sevoflurane at MAC. Methods: Indwelling lumbar subarachnoid catheters were surgically placed in 14 anesthetized rats. Rats were anesthetized with sevoflurane the next day, and a pre-infusion sevoflurane MAC was measured in duplicate using a tail clamp method. Artificial CSF (aCSF) containing either 0 or 4 mg/mL strychnine was then infused intrathecally at 4 μL/min, and the post-infusion baseline sevoflurane MAC was measured. Finally, aCSF containing strychnine (either 0 or 4 mg/mL) plus 0.4 mg/mL dizocilpine (MK-801) was administered intrathecally at 4 μL/min, and the post- dizocilpine sevoflurane MAC was measured. Results: Pre-infusion sevoflurane MAC was 2.26%. Intrathecal aCSF alone did not affect MAC, but intrathecal strychnine significantly increased sevoflurane requirement. Addition of dizocilpine significantly decreased MAC in all rats, but this decrease was two times larger in rats without intrathecal strychnine compared to rats with intrathecal strychnine, a statistically significant (P < 0.005) difference that is consistent with increased NMDA receptor antagonism by sevoflurane in rats receiving strychnine.
    [Show full text]